Effectiveness, tolerability and safety of Rileptid in psychiatric practice
28 patients with schizophrenia were treated with Rileptid (risperidone) and were assessed by CGI-S and CGI-I scales during 2 months (visits on 7<sup>th</sup>, 14<sup>th</sup>, 28<sup>th</sup> and 56<sup>th</sup> days). Significant improving was registered in 80% of cases. The results showed high effectiveness and safety of Rileptid in clinical practice for the treatment of acute and subacute states in patients with schizophrenia.